Journal of Clinical Oncology, Vol 5, 310-317, Copyright © 1987 by American Society of Clinical Oncology
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B
G Lopez-Berestein, GP Bodey, LS Frankel and K Mehta
Nine patients with hematologic malignancies developed fungal infections,
predominantly involving the liver and spleen. Eight patients had
biopsy-documented progressive candidiasis and one had an unclassified
fungus. The patients were treated with liposomal- amphotericin B (L-AmpB)
after their fungal infection progressed during treatment with standard
intravenous (IV) AmpB (Fungizone; E. R. Squibb & Son, Princeton, NJ)
and/or other antifungals. Eight patients (88.8%) were cured of their fungal
infection, and one showed improvement after treatment. Minor acute toxicity
and no chronic toxicity were associated with the administration of L-AmpB.
L-AmpB is a safe and effective therapeutic method for treating fungal
infections that have invaded the liver and spleen even when they are
refractory to conventional anti- fungal therapy.